-
Good Practice on the assessment of GMO-related aspects in the context of clinical trials with human cells genetically modified by means of viral vectors v5 15-09-2023 Good Practice on the assessment of GMO-related aspects in the context of clinical trials with human cells genetically modified by means of viral vectors v5PDF | 471,66 kB
-
Common Application form for clinical research with human cells genetically modified by means of viral vectors v5 15-09-2023 Common Application form for clinical research with human cells genetically modified by means of viral vectors v5DOCX | 30,30 kB
-
Voorbeelden meldingscategorieën Rggo art35c 12-01-2023 Voorbeelden meldingscategorieën Rggo art35cPDF | 110,63 kB
-
Wijziging Regeling ggo 2013 tav meldingen klinische studies 12-01-2023 Wijziging Regeling ggo 2013 tav meldingen klinische studiesPDF | 1,47 MB
-
-
-
Gestandaardiseerde MRB VOV gm cellen AAV (art39d) 11-01-2023 Gestandaardiseerde MRB VOV gm cellen AAV (art39d)PDF | 598,01 kB
-
10-2021 Guidance document VOV art 39d gm-cells AAV 11-01-2023 10-2021 Guidance document VOV art 39d gm-cells AAVDOCX | 34,92 kB
-
application form VOV gm cells_art39d_2022-12 v1.1_EN 11-01-2023 application form VOV gm cells_art39d_2022-12 v1.1_ENDOCX | 44,78 kB
-
application form VOV gm cells_art39c_2022-12 v1.1_EN 11-01-2023 application form VOV gm cells_art39c_2022-12 v1.1_ENDOCX | 45,98 kB
Rijksinstituut voor Volksgezondheid en Milieu
Ministerie van Volksgezondheid, Welzijn en Sport